Genmab A/S (Nasdaq: GMAB, 0MGB), the Copenhagen-headquartered international biotechnology company, has published a company announcement disclosing share transactions carried out by managerial employees and their closely associated persons, in compliance with Article 19 of EU Market Abuse Regulation No. 596/2014 and Implementing Regulation 2016/523. The disclosure, dated 11 November 2026, confirms that Genmab's managerial employees have granted the company power of attorney to publish these trading disclosures on their behalf. Investors monitoring insider activity at the antibody medicines specialist may find the filing relevant as a routine but legally required transparency measure under European securities law.

Key Points

  • Genmab A/S (Nasdaq: GMAB, 0MGB), headquartered in Copenhagen, Denmark
  • Managerial employee share transactions disclosed under Article 19 of EU Market Abuse Regulation No. 596/2014
  • Specific transaction volumes, values, and individual names are contained in the attached document; no aggregate figures were stated in the announcement body
  • Investors should review the attached filing — titled "111126_CA48_Managerial Employee Transactions" — for full transaction-level detail

Genmab's EU Market Abuse Regulation Disclosure Obligations and Power of Attorney Arrangement

The announcement confirms that Genmab A/S has published the transaction data in accordance with its obligations under Article 19 of Regulation No. 596/2014 on Market Abuse and the associated Implementing Regulation 2016/523. A distinctive feature of Genmab's compliance approach, as stated in the announcement, is that managerial employees and their closely associated persons have granted the company a power of attorney, enabling Genmab to publish these trading disclosures centrally on their behalf. The specific details of individual transactions are contained within the attached document rather than the main announcement text.

Genmab's Antibody Medicine Portfolio and Eight Approved Therapies Underpin Disclosure Context

Genmab was established in 1999 and describes itself as an international biotechnology company focused on improving outcomes for people with cancer and other serious diseases through antibody medicines. The company's science currently underpins eight approved antibody medicines, and it operates a late-stage clinical pipeline that includes wholly owned programmes. Its therapeutic formats span bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies, and other next-generation modalities developed over more than 25 years of research activity.

Genmab's Global Footprint Across Denmark, North America, Europe and Asia Pacific

Genmab maintains its registered headquarters at Carl Jacobsens Vej 30, Valby, Denmark, with a CVR number of 2102 3884 and an LEI code of 529900MTJPDPE4MHJ122. Beyond its Danish base, the company holds an international presence spanning North America, Europe, and Asia Pacific. This geographic spread is relevant context for investors, as clinical development, regulatory, and commercial activities across multiple jurisdictions introduce execution and regulatory risks that Genmab acknowledges in its standard forward-looking risk disclosures, with further detail available in its most recent Annual Report on Form 20-F filed with the US Securities and Exchange Commission.